To study the role of febuxostat in decreasing adverse effects of free radicals in cardiac surgery

Phase 2

Completed

• Conditions: Health Condition 1: I00-I99- Diseases of the circulatory system

• Registration Number: CTRI/2021/01/030807
• Lead Sponsor: AIIMS

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2023-08-25
• Last Update Posted: 18 September 2023

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

As per parameters defined above all adult patients undergoing cardiac surgery under with overall EUROSCORE II < 20%

Specific parameters: -

- Age 18- 65

- Elective and Urgent procedure

- Weight of procedure –

1.Isolated CABG

2.Isolated non-CABG major procedure (e.g. single valve procedure, replacement of ascending aorta, correction of septal defect, etc)

3.2 major procedures (e.g. CABG and AVR), or CABG and mitral valve repair (MVR), or AVR and replacement of ascending aorta, or CABG and maze procedure, or AVR and MVR, etc

Exclusion Criteria

1Cyanotic heart disease

2Off pump procedure, DHCA

3Emergency and salvage procedures

4=3 major procedures (e.g. AVR, MVR, and CABG, or MVR, CABG, and tricuspid annuloplasty, etc), or aortic root replacement when it includes AVR or repair, coronary reimplantation, and root and ascending replacement

5Severe renal dysfunction

- =50 mL/min

- On dialysis (regardless of serum creatinine)

6NYHA Class IV: symptoms at rest

7Poor (LVEF 21-30%), Very poor (LVEF =20%)

8Active infection

Study & Design

• Study Type: Interventional
• Study Design: Not specified